Kuros and Synthes Inc. announce license and development agreement
Commenting on today’s announcement, Mr. Didier Cowling, CEO of Kuros, said: “We are delighted to have signed this deal related to our synthetic matrix technologies with Synthes. Partnering our products with leading marketing partners is a key element of Kuros’ strategy and we are looking forward to a productive working relationship with Synthes”.
Michel Orsinger, President and CEO of Synthes, commented on the partnership: "The Kuros partnership is an important addition to Synthes goal of being a total solutions provider for our customers. The partnership will strengthen both Kuros and Synthes commitment to develop patient focused clinical solutions."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.